Kurs & Likviditet
Kalender
2024-11-12 | Kvartalsrapport 2024-Q3 |
2024-07-25 | Kvartalsrapport 2024-Q2 |
2024-04-25 | Kvartalsrapport 2024-Q1 |
2024-04-11 | Årsstämma 2024 |
2024-02-22 | Halvårsutdelning AZN 20.65 |
2024-02-08 | Bokslutskommuniké 2023 |
2023-11-09 | Kvartalsrapport 2023-Q3 |
2023-08-10 | Halvårsutdelning AZN 9.64 |
2023-07-28 | Kvartalsrapport 2023-Q2 |
2023-04-27 | Årsstämma 2023 |
2023-04-27 | Kvartalsrapport 2023-Q1 |
2023-02-23 | Halvårsutdelning AZN 20.69 |
2023-02-09 | Bokslutskommuniké 2022 |
2022-11-10 | Kvartalsrapport 2022-Q3 |
2022-08-11 | Halvårsutdelning AZN 9.49 |
2022-07-29 | Kvartalsrapport 2022-Q2 |
2022-04-29 | Kvartalsrapport 2022-Q1 |
2022-04-29 | Årsstämma 2022 |
2022-02-24 | Halvårsutdelning AZN 18 |
2022-02-10 | Bokslutskommuniké 2021 |
2021-11-12 | Kvartalsrapport 2021-Q3 |
2021-08-12 | Halvårsutdelning AZN 7.72 |
2021-07-29 | Kvartalsrapport 2021-Q2 |
2021-05-11 | Årsstämma 2021 |
2021-04-30 | Kvartalsrapport 2021-Q1 |
2021-02-25 | Halvårsutdelning AZN 15.76 |
2021-02-11 | Bokslutskommuniké 2020 |
2020-11-05 | Kvartalsrapport 2020-Q3 |
2020-08-13 | Halvårsutdelning AZN 7.87 |
2020-07-30 | Kvartalsrapport 2020-Q2 |
2020-04-29 | Årsstämma 2020 |
2020-04-29 | Kvartalsrapport 2020-Q1 |
2020-02-27 | Halvårsutdelning AZN 18.32 |
2020-02-14 | Bokslutskommuniké 2019 |
2019-10-24 | Kvartalsrapport 2019-Q3 |
2019-08-08 | Halvårsutdelning AZN 8.49 |
2019-07-25 | Kvartalsrapport 2019-Q2 |
2019-04-26 | Kvartalsrapport 2019-Q1 |
2019-04-26 | Årsstämma 2019 |
2019-02-28 | Halvårsutdelning AZN 17.46 |
2019-02-14 | Bokslutskommuniké 2018 |
2018-11-08 | Kvartalsrapport 2018-Q3 |
2018-08-09 | Halvårsutdelning AZN 7.92 |
2018-07-26 | Kvartalsrapport 2018-Q2 |
2018-05-18 | Kvartalsrapport 2018-Q1 |
2018-05-18 | Årsstämma 2018 |
2018-02-15 | Halvårsutdelning AZN 14.97 |
2018-02-02 | Bokslutskommuniké 2017 |
2017-11-09 | Kvartalsrapport 2017-Q3 |
2017-08-10 | Halvårsutdelning AZN 7.4 |
2017-07-27 | Kvartalsrapport 2017-Q2 |
2017-04-27 | Årsstämma 2017 |
2017-04-27 | Kvartalsrapport 2017-Q1 |
2017-02-16 | Halvårsutdelning AZN 16.57 |
2017-02-02 | Bokslutskommuniké 2016 |
2016-11-10 | Kvartalsrapport 2016-Q3 |
2016-08-11 | Halvårsutdelning AZN 7.81 |
2016-07-28 | Kvartalsrapport 2016-Q2 |
2016-04-29 | Kvartalsrapport 2016-Q1 |
2016-04-29 | Årsstämma 2016 |
2016-02-18 | Halvårsutdelning AZN 16.26 |
2016-02-04 | Bokslutskommuniké 2015 |
2015-11-05 | Kvartalsrapport 2015-Q3 |
2015-08-13 | Halvårsutdelning AZN 7.71 |
2015-07-30 | Kvartalsrapport 2015-Q2 |
2015-04-24 | Kvartalsrapport 2015-Q1 |
2015-04-24 | Årsstämma 2015 |
2015-02-19 | Halvårsutdelning AZN 15.62 |
2015-02-05 | Bokslutskommuniké 2014 |
2014-11-06 | Kvartalsrapport 2014-Q3 |
2014-08-13 | Halvårsutdelning AZN 6.2 |
2014-07-31 | Kvartalsrapport 2014-Q2 |
2014-04-24 | Kvartalsrapport 2014-Q1 |
2014-04-24 | Årsstämma 2014 |
2014-02-19 | Halvårsutdelning AZN 12.41 |
2014-02-06 | Bokslutskommuniké 2013 |
2013-10-31 | Kvartalsrapport 2013-Q3 |
2013-08-14 | Halvårsutdelning AZN 5.92 |
2013-08-01 | Kvartalsrapport 2013-Q2 |
2013-08-01 | Analytiker möte 2013 |
2013-04-25 | Kvartalsrapport 2013-Q1 |
2013-04-25 | Årsstämma 2013 |
2013-02-13 | Halvårsutdelning AZN 12.08 |
2013-01-31 | Bokslutskommuniké 2012 |
2012-10-25 | Kvartalsrapport 2012-Q3 |
2012-10-25 | Analytiker möte 2012 |
2012-08-08 | Halvårsutdelning AZN 6.26 |
2012-07-26 | Kvartalsrapport 2012-Q2 |
2012-04-26 | Kvartalsrapport 2012-Q1 |
2012-04-26 | Årsstämma 2012 |
2012-02-15 | Halvårsutdelning AZN 13.21 |
2012-02-02 | Bokslutskommuniké 2011 |
2011-10-27 | Kvartalsrapport 2011-Q3 |
2011-08-03 | Halvårsutdelning AZN 5.33 |
2011-07-28 | Kvartalsrapport 2011-Q2 |
2011-04-28 | Årsstämma 2011 |
2011-04-28 | Kvartalsrapport 2011-Q1 |
2011-02-02 | Halvårsutdelning AZN 11.99 |
2011-01-27 | Bokslutskommuniké 2010 |
2010-10-28 | Kvartalsrapport 2010-Q3 |
2010-08-04 | Halvårsutdelning AZN 5.12 |
2010-07-29 | Kvartalsrapport 2010-Q2 |
2010-04-29 | Kvartalsrapport 2010-Q1 |
2010-02-03 | Halvårsutdelning AZN 12.43 |
2010-01-28 | Bokslutskommuniké 2009 |
2009-10-29 | Kvartalsrapport 2009-Q3 |
2009-08-05 | Halvårsutdelning AZN 4.41 |
2009-07-30 | Kvartalsrapport 2009-Q2 |
2009-04-30 | Kvartalsrapport 2009-Q1 |
2009-04-30 | Årsstämma 1 |
2009-02-04 | Halvårsutdelning AZN 12.02 |
2008-08-06 | Halvårsutdelning AZN 3.34 |
2008-02-06 | Halvårsutdelning AZN 8.61 |
2007-08-08 | Halvårsutdelning AZN 3.49 |
2007-02-07 | Halvårsutdelning AZN 8.6 |
2006-08-09 | Halvårsutdelning AZN 3.6 |
2006-02-08 | Halvårsutdelning AZN 7.02 |
2005-08-10 | Halvårsutdelning AZN 2.99 |
2005-02-09 | Halvårsutdelning AZN 4.497 |
2004-08-11 | Halvårsutdelning AZN 2.2 |
2004-02-18 | Halvårsutdelning AZN 3.91 |
2003-08-20 | Halvårsutdelning AZN 2.07 |
2003-02-19 | Halvårsutdelning AZN 3.99 |
2002-08-21 | Halvårsutdelning AZN 2.21 |
2002-02-20 | Halvårsutdelning AZN 5.01 |
2001-08-22 | Halvårsutdelning AZN 2.44 |
2001-02-21 | Halvårsutdelning AZN 4.49 |
2000-09-04 | Halvårsutdelning AZN 2.1 |
2000-03-08 | Halvårsutdelning AZN 4.01 |
1999-09-06 | Halvårsutdelning AZN 1.89 |
1999-04-01 | Split AZN 1:0.5045 |
1997-05-26 | Split AZN 1:2 |
1993-06-14 | Split AZN 1:5 |
1987-06-04 | Split AZN 1:2 |
Beskrivning
Land | Storbritannien |
---|---|
Lista | Large Cap Stockholm |
Sektor | Hälsovård |
Industri | Läkemedel & Handel |
Move brings together AstraZeneca and Alexion colleagues in a purpose-built facility in Kendall Square, Cambridge, MA, a world leading life sciences hub.
AstraZeneca today announced plans to open a new site at the heart of the Cambridge, MA, life sciences and innovation hub.
The new site will be a strategic R&D centre for AstraZeneca, as well as Alexion's new corporate headquarters. The site will bring together approximately 1,500 R&D, commercial and corporate colleagues into a single purpose-built space in Kendall Square, Cambridge, MA.
The site, scheduled for completion in 2026, will be in close proximity to several major academic, pharma and biotech institutions, inspiring greater collaboration and innovation potential, and providing access to future talent. The move reinforces AstraZeneca's commitment to the greater Boston area, with over 570,000 square feet of R&D and commercial space, and room for expansion for the future.
Pascal Soriot, Chief Executive Officer, AstraZeneca, said: "Today's announcement is a milestone moment following the acquisition of Alexion in July 2021. Our combined company has already successfully leveraged internal scientific synergies, and this move will act as a catalyst for even more external collaboration and innovation.
"Kendall Square, Cambridge, is at the heart of the life sciences and innovation hub of the greater Boston area, and our new site will put us right at the centre of this space. The move will provide access to some of the most innovative partners in academia and biotech, offering opportunities to accelerate our growth and collaborate with like-minded organisations as we continue to push the boundaries of science to deliver advances for patients."
Notes
AstraZeneca is working with BXP (NYSE:BXP) on development of the new site.
In line with AstraZeneca's commitment to leading in sustainability, the aim is for the new site to have platinum Leadership in Energy & Environmental Design (LEED) certification, the highest level of certification.
Alexion's R&D center of excellence will remain in New Haven, Connecticut. Alexion recently signed a lease to expand that campus as well, which will double Alexion's lab floor space in New Haven by the end of 2023.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com (http://www.astrazeneca.com/) and follow the Company on Twitter @AstraZeneca (https://twitter.com/AstraZeneca).
Contacts
For details on how to contact the Investor Relations Team, please click here (https://www.astrazeneca.com/investor-relations.html#Contacts). For Media contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html).